MAPT and tauopathy: Currently, tau-targeted disease-modifying therapies developed for AD or other tauopathies mainly include mediators of tau post-translational modifications, anti-tau immunotherapy (active and passive), tau aggregation inhibitors, microtubule stabilizers, and gene therapy.